(P79) Azurion 7 B20
Payments companies reported to CMS as associated with (P79) Azurion 7 B20. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with (P79) Azurion 7 B20, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with (P79) Azurion 7 B20
These are the largest totals companies reported as associated with (P79) Azurion 7 B20. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Yourong Su | Chicago, IL | Neurological Surgery | $1,050.54 |
| Chetan Velagapudi | Merrillville, IN | Vascular & Interventional Radiology | $1,043.32 |
| Thinesh Sivapatham | Newark, DE | Diagnostic Radiology | $847.86 |
| Ibrahim Abdullah | Omaha, NE | Surgery | $609.55 |
| Nicole Sutton | Bronx, NY | Pediatric Cardiology | $589.85 |
| Alexander Misono | Newport Beach, CA | Vascular & Interventional Radiology | $545.16 |
| Christopher Baker | Bozeman, MT | Radiation Oncology | $518.14 |
| Jose Marino Granados | Worcester, MA | Vascular Neurology | $393.08 |
| Gaurav Jindal | Warwick, RI | Diagnostic Radiology | $159.41 |
| Michael Rinaldi | Charlotte, NC | Cardiovascular Disease | $109.09 |
Prescribed (P79) Azurion 7 B20?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.